Medical/Pharmaceuticals

Fosun International 2024 Annual Results Presentation: Aiming for RMB10 Billion in Future Industrial Operation Profit

HONG KONG and SHANGHAI, April 2, 2025 /PRNewswire/ -- On 1 April 2025, Fosun International Limited (HKEX stock code: 00656, "Fosun International"), together with its subsidiaries ("Fosun" or the "Group") held its 2024 annual results presentation inShanghai. The results presentation was attended b...

2025-04-02 13:51 5044

Hanmi Pharmaceutical's 'Gugutams' to be Launched in Mexico as 'Aditams', Marking the Start of Full-Scale Latin America Expansion

Hanmi Pharm Begins Local Sales of Urological Product 'Aditams' in Mexico with Partner 'Laboratorios Silanes'  Launch completed in February, Hanmi Pharm's Third Product to Enter Latin America Aditams, The First Urological Combination Drug for OPG and ED Exported to Mexico SEOUL, South Korea, Ap...

2025-04-02 12:17 2936

Human Frontier Science Program: Research Grants Awarded to 104 of the Most Pioneering Scientists from 30 Nations

STRASBOURG, France, April 2, 2025 /PRNewswire/ -- To pioneer new frontiers in life science research, the Human Frontier Science Program has awarded 104 of the world's most ingenious scientists from 30 nations with 2025 HFSP Research Grants and the first round of the new Accelerator Grants. 

2025-04-02 08:10 2634

Telix Announces First Patient Dosed in First-in-Human ZOLAR Trial of TLX300-CDx in Advanced Soft Tissue Sarcoma

MELBOURNE, Australia, April 2, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that a first patient has been dosed in the Phase 1 ZOLAR[1] trial of TLX300-CDx (89 Zr-olaratumab) in patients with advanced, metastatic soft tissue sarcoma...

2025-04-02 03:30 2895

Yingli Pharma Announces Successful End-of-Phase 2 Meeting with FDA and Clearance of Global Multi-center Phase 3 Registration Study Design of Linperlisib for the Treatment of Relapsed and/or Refractory Peripheral T-cell Lymphoma

SAN FRANCISCO, April 1, 2025 /PRNewswire/ -- Shanghai Yingli Pharmaceutical Co., Ltd. (Yingli Pharma), a clinical stage biotechnology company developing oral small molecule drugs for cancer, metabolic, and immune diseases, announced today that it has received clearance from the US Food and Drug A...

2025-04-01 22:00 3018

Senior Vice President at United Imaging Inducted to the AIMBE College of Fellows

HOUSTON, April 1, 2025 /PRNewswire/ -- United Imaging, a global manufacturer of modern medical imaging technology, is proud to announce thatLingzhi (Lance) Hu, Ph.D., Senior Vice President and Chief Technology Officer of United Imaging Research at United Imaging, has been inducted into the 2025 C...

2025-04-01 21:00 2225

Peijia Medical collaborates with dsm-firmenich to create groundbreaking innovative medical device products

SUZHOU, China, April 1, 2025 /PRNewswire/ -- Today, April 1st, Peijia Medical Technology (Suzhou) Co., Ltd. held a strategic innovation cooperation signing ceremony and a press conference to announce the research and development achievements of polymer heart valves using ultra-high molecular weig...

2025-04-01 20:00 3091

Dizal Announces DZD8586 and DZD6008 Presentations at 2025 ASCO Annual Meeting

SHANGHAI, April 1, 2025 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced today that results of its investigational drug candidatesDZD8586 and DZD6008, have been selected for pr...

2025-04-01 18:18 2725

PeptiGrowth Inc. is Launching a Novel Synthetic Peptide: KGF alternative peptide (FGFR2b agonist)

TOKYO, April 1, 2025 /PRNewswire/ -- PeptiGrowth Inc. (Headquarters: Chiyoda-ku, Tokyo, President: Junichiro Ishizuka) has successfully developed a novel synthetic peptide called "KGF alternative- peptide (FGFR2b agonist)" which is functionally equivalent to recombinant keratinocyte growth factor ...

2025-04-01 14:30 2355

ECHO IQ SIGNS STRATEGIC PARTNERSHIP AND INTEGRATION AGREEMENTS WITH SCIMAGE AND MEDAXIOM TO EXPAND ECHOSOLV AS ACROSS 36 US CARDIOLOGY NETWORKS

* EchoSolv AS will be fully integrated into ScImage's medical workflow platform, facilitating streamlined deployment within MedAxiom's hospital and cardiology networks. * ScImage is a nationally recognised Cloud and integrated workflow management platform, with over 1,200 users, specialisin...

2025-04-01 13:39 2708

Merck Exercised the Option for the Global Rights of Abbisko Therapeutics's Pimicotinib

SHANGHAI, March 31, 2025 /PRNewswire/ -- On April 1, 2025, Beijing Time, Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics") announced that Merck has exercised the global commercialization option for pimicotinib (ABSK021), with an option exercise fee ofUSD85.0 million, under the licensing agr...

2025-04-01 08:48 3608

Luye Pharma's Rivastigmine Twice Weekly Transdermal Patch Approved for Marketing in Japan for the Treatment of Alzheimer's Dementia

TOKYO, March 31, 2025 /PRNewswire/ -- Luye Pharma Group today announced that marketing approval for its innovative formulation Rivastigmine Twice Weekly Transdermal Patch has been granted by the Japanese Ministry of Health, Labour and Welfare as a new drug, indicated for suppression of progressio...

2025-03-31 21:35 2998

Lunit Announces Partnership with the National Cancer Institute to Advance AI-Powered Biomarker Research

Collaboration to apply Lunit's AI technologies across NCI's broad spectrum of cancer studies, aiming to accelerate personalized cancer care SEOUL, South Korea, March 31, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics...

2025-03-31 21:00 2435

Ascletis Announces Positive Interim Results from Its U.S. Phase Ib Trial with ASC30, a Potentially First-in-Class Subcutaneous Injection Small Molecule GLP-1R Agonist

-Ultra-long-acting subcutaneous (SQ) injection formulation of small molecule ASC30 demonstrated a 36-day half-life in patients with obesity, supporting once monthly or less frequent administration. -As previously disclosed, oral tablet formulation of small molecule ASC30 demonstrated potentially ...

2025-03-31 19:00 2588

Harbour BioMed Reports Full Year 2024 Financial Results

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 31, 2025 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced its ...

2025-03-31 18:13 3371

Clinical Study demonstrates Kerry Group Supplement Solution Sensoril® Ashwagandha Supports Quality of Life for Post-Menopausal Women

Sensoril® Ashwagandha is among Kerry's portfolio of solutions tailored to meet women's unique health needs   SINGAPORE, March 31, 2025 /PRNewswire/ -- Sensoril® ashwagandha  — a science-backed ingredie...

2025-03-31 17:30 3029

Revenue Soars 44%, Basecare Medical (2170.HK) Advances Toward Global Intelligent Manufacturing

SUZHOU, China, March 31, 2025 /PRNewswire/ -- Amid frequent pro-fertility policy updates, Basecare Medical, a pioneer in the assisted reproductive IVD sector with full fertility health industry chain coverage, released its stellar 2024 performance report. The company achieved annual revenue of ne...

2025-03-31 17:01 4339

Reaffirming Leadership: Medit's Strong Presence at IDS 2025

COLOGNE, Germany and SEOUL, South Korea, March 31, 2025 /PRNewswire/ -- Medit, a global leader in digital dentistry solutions, made a significant impact at International Dental (IDS) 2025 by unveiling its latest innovations in intraoral scanning and comprehensive digital workflows. Alongside new ...

2025-03-31 15:00 3054

S Spine Hospital Launches T-Shirt to Raise Awareness About Back Pain

BANGKOK, March 31, 2025 /PRNewswire/ -- S Spine Hospital, a specialist in spine, has unveiled "THE SPINE T-SHIRT," a health communication initiative designed to transform how people perceive and understand spinal health issues. S Spine Hosp...

2025-03-31 14:52 1923

Ceva Animal Health renews its shareholding structure with all its long-standing partners and opens its capital to Mérieux Institute and ARCHIMED to accelerate its growth.

LIBOURNE, France, March 31, 2025 /PRNewswire/ -- Ceva Animal Health  (Ceva), the world's fifth-largest animal health company, announces the restructuring of its capital. All investors, whether "Friends of Ceva" or pure investors led by Temasek, have renewed their investmen...

2025-03-31 14:12 3134
1 ... 111112113114115116117 ... 644

Week's Top Stories